Triazine Derivatives as Src Kinase Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for protein kinase-mediated diseases lack effective therapeutic agents, with a need for new compounds that can inhibit protein kinases to modulate aberrant pathways driving oncologic transformation and other conditions such as cancer, autoimmune diseases, and inflammation.
Innovation Solution
Development of triazine derivatives that act as kinase inhibitors, specifically targeting Src family kinases, to block enzymatic activity and modulate kinase activity, thereby treating various diseases associated with cellular proliferation and hyperproliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used for protein kinase-mediated diseases, then treatment is provided, but effective therapeutic agents are lacking and treatment options are insufficient
Solution Approach 1:
The patent employs parameter changes by systematically varying the chemical structure of triazine derivatives (changing molecular parameters such as substituents at positions 2, 4, and 6 of the triazine ring) to optimize kinase inhibitory activity. This allows generation of multiple compounds with different potencies and selectivities, addressing the need for both effective therapy and diverse treatment options.
Solution Approach 2:
The patent segments the broad category of protein kinases into specific families (Src family, EGFR, HER2, etc.) and develops targeted inhibitors for each. This segmentation allows creation of specialized therapeutic agents with high selectivity for specific kinase targets, thereby improving therapeutic effectiveness while providing multiple针对不同 disease mechanisms treatment options.
2Reliability
If triazine derivatives are developed to inhibit protein kinases, then kinase activity is modulated and aberrant pathways are blocked, but new compounds need to be synthesized and characterized
Solution Approach 1:
The patent establishes a universal triazine core structure (1,3,5-triazine ring) that serves as a multi-functional platform for generating multiple kinase inhibitors. By maintaining the core structure and varying only the substituents, the patent simplifies synthesis while achieving inhibition of multiple kinase targets (Src, EGFR, HER2, etc.), thus improving efficacy without proportionally increasing manufacturing complexity.
Solution Approach 2:
The patent uses standardized intermediate compounds in the synthesis pathway of triazine derivatives. By preparing common intermediates (such as substituted cyanuric chlorides or amines) that can be used to generate multiple final products, the patent reduces overall synthesis complexity and facilitates easier manufacturing of various inhibitor variants.
Data Source
Figure 1
AI summary
The invention provides for Triazine derivatives and their use to modulate protein kinase activity in a variety of conditions and diseases.